期刊文献+

磷酸西他列汀的合成 被引量:4

Synthesis of Sitagliptin Phosphate
原文传递
导出
摘要 2,4,5-三氟苯乙酸与丙二酸单乙酯钾盐经亲核取代、脱羧、不对称还原、酯水解、与苄氧胺盐酸盐反应后经Mitsunobu反应得到(R)-1-苄氧基-4-(2,4,5-三氟苄基)-氮杂环丁烷-2-酮,再经水解开环后与5,6,7,8-四氢-3-三氟甲基-1,2,4-三唑并[4,3-a]吡嗪盐酸盐经缩合并脱保护基得到西他列汀,最后与磷酸成盐得到磷酸西他列汀,总收率约58%,光学纯度99.8%。 Sitagliptin phosphate was synthesized from 2,4,5-trifluorophenylacetic acid by substitution with ethyl potassium malonate, decarboxylation, asymmetric reduction, hydrolysis, reaction with O-benzyl hydroxylamine hydrochloride and then Mitsunobu reaction to give (R)-l-benzyloxy-4-(2,4,5-trifluorobenzyl)-2-azacyclobutanone, which was subjected to hydrolysis and then condensation with 5,6,7,8-tetrahydro-3-trifluoromethyl-l,2,4-triazolo L4,3- a] pyrazine hydrochloride, followed by deprotection and salification with an overall yield of about 58 %, with an optical purity of 99.8 %.
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2011年第8期561-564,共4页 Chinese Journal of Pharmaceuticals
关键词 磷酸西他列汀 2型糖尿病 合成 sitagliptin phosphate type 2 diabetes synthesis
  • 相关文献

参考文献11

  • 1许菁,王玉丽,徐为人,张士俊.治疗2型糖尿病的新型药物——西他列汀[J].中国药物与临床,2007,7(11):861-863. 被引量:8
  • 2夏玲红.治疗糖尿病的新药西他列汀[J].中国新药杂志,2007,16(12):979-981. 被引量:26
  • 3丁明,姜涛.治疗2型糖尿病新药--磷酸西他列汀[J].中国药房,2008,19(1):58-60. 被引量:9
  • 4孙桂芳,蔡正艳,周伟澄.西他列汀合成路线图解[J].中国医药工业杂志,2008,39(5):383-386. 被引量:12
  • 5Kim D, Wang LP, Beconi M. (2R)-4-Oxo-4-[3- (trifluoromethyl) -5,6-dihydro [ 1,2,4] triazolo [4,3-a] pyrazin- 7 (8H) -yl] -1- (2,4,5-trifluorophenyl) butan-2-amine: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes [J]. J Med Chem, 2005, 48 (1) : 141-151.
  • 6Hansen KB, Balsells J, Dreher S, et al. First generation process for the preparation of the DPP-IV inhibitor sitagliptin [J]. Org Process Res Dev, 2005, 9 (5) : 634-639.
  • 7Dreher SD, Ikemoto N, Niolito E, et al. Process to chiral β-amino acid derivatives: WO, 2004085661 [P]. 2004-10-07. (CA 2004, 141: 332476).
  • 8肖毅,阿姆斯特隆三世JD,克尔斯卡SW,等.通过不对称氢化来制备手性β-氨基酸衍生物的方法:中国,1761642[P].2007-09-26.
  • 9Kubryk M, Hansen KB. Application of the asymmetric hydrogenation of enamines to the preparation of a β-amino acid pharmacophore [J]. Tetrahedron Asymm, 2006, 17 (2) : 205-209.
  • 10King SA, Thompson AS, King AO, et al. An improved procedure for the synthesis and use of [RuCI2 (BINAP) ] 2.NEt3. Dependence of the Ru ( Ⅱ ) - B1NAP catalyzed asymmetric hydrogenation of !3-keto esters on trace amounts of acid [J]. J Org Chem, 1992, 57 (25): 6689-6691.

二级参考文献53

  • 1HERMAN GA,BERGMAN A,STEVENS C,et al.Effect of single oral doses of sitagliptin,a dipeptidyl peptidase-4 inhibitor,on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes[J].J Clin Endocrinol Metab,2006,91 (11):4612-4619.
  • 2BERGMAN AJ,STEVENS C,ZHOU Y,et al.Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin,a dipeptidyl peptidase-Ⅳ inhibitor:a double-blind,randomized,placebo-controlled study in healthy male volunteers[J].Clin Ther,2006,28(1):55 -72.
  • 3HERMAN GA,BERGMAN A,LIU F,et al.Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitaglipin in middle-aged obese subjects[J].J Clin Pharmacol,2006,46(8):876 -886.
  • 4HERMAN GA,STEVENS C,VAN DYCK K,et al.Pharmacokinetics and pharmacodynamics of sitagliptin,an inhibitor of dipeptidyl peptidase Ⅳ,in healthy subjects:results from two randomized,double-blind,placebo-controlled studies with single oral doses[J].Clin Pharmacol Ther,2005,78(6):675 -688.
  • 5VINCENT SH,REED JR,BERGMAN AJ,et al.Metabolism and excretion of the DPP-4 inhibitor[14C] sitagliptin in humans[J].Drug Metab Dispos,2007,35(4):533 -538.
  • 6RAZ I,HANEFELD M,XU L,et al.Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitsgliptin as monotherapy in patients with type 2 diabetes mellitus[J].Diabetologia,2006,49(11):2564 -2571.
  • 7ASCHNER P,KIPNES MS,LUNCEFORD JK,et al.Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes[J].Diabetes Care,2006,29(12):2632 -2637.
  • 8SCOTT R,WU M,SCANCHEZ M,et al.Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes[J].Int J Clin Pract,2007,61(1):171 -180.
  • 9CHARBONNEL B,KARASIK A,LIU J,et al.Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone[J].Diabetes Care,2006,29(12):2638 -2643.
  • 10ROSENSTOCK J,BRAZG R,ANDRYUK PJ,et al.Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2diabetes:a 24-week,multicenter,randomized,doubleblind,placebo-controlled,parallel-group study[J].Clin Ther,2006,28(10):1556-1568.

共引文献45

同被引文献32

  • 1袁哲东,王强,俞雄,张秀平.消旋卡多曲的合成[J].中国医药工业杂志,2006,37(5):293-294. 被引量:5
  • 2许菁,王玉丽,徐为人,张士俊.治疗2型糖尿病的新型药物——西他列汀[J].中国药物与临床,2007,7(11):861-863. 被引量:8
  • 3XIAO Yi, JOSEPH D, KRSKA S W, et al. Process for the preparation of chiral beta amino acid deriva-fives by asymmetric hydrogenation :WO ,2004085378 [ P]. 2004 - 03 - 15.
  • 4DREHER S D, IKEMOTO N, NIOLITO E, et al. Process to chiral /3-amino acid derivatives: WO, 2004085661 [ P]. 2004 - 10 - 07.
  • 5PADI P R, IRENI B, POLAVARAPU S, et al. Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof: WO, 2009085990 [ P ]. 2009 - 07 - 09.
  • 6KIM D,WANG L P,BECONI M. (2R)-4-E3-(Trif- luorornethyl) -5,6-dihydro I 1,2,4 ] triazolo E 4,3-a ] pyrazin-7 (8H) -yl] -1- (2,4,5-trifluoromethyl) butan- 2-amine:a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes[ J]. J IVied Chem,2005,48( 1 ) :141 -151.
  • 7KUBRYK M, HANSEN K B. Application of the asymmetric hydrogenation of enarnines to the prepa- ration of a/3-amino acid plaarmacophore [ J ]. Tetra- hedron: Asymmetry, 2006,17 (2) : 205 - 209.
  • 8SUN Piao-yang, CHEN Yong-jiang, YU Guang-liang. Process for preparing R-fl-anfino phenylbutyric acid derivatives: US,8580997[ P]. 2013 - 11 - 12.
  • 9LIN Kuai-le, CAI Zheng-yan, ZHOU Wei-cheng. Practical and economical approach to synthesize sita- gliptin [ J ]. Synth Commun, 2013,43 ( 24 ) : 3281 - 3286.
  • 10GIDWANI R M, HIREMATH C. Crystalline salts of sitagliptin: WO,2010000469 [ P ]. 2010 - 01 - 07.

引证文献4

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部